(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will ...
Shares of Novavax surged after the company disclosed a $1.4 billion licensing deal with Sanofi. The stock was up 72% at $7.66 in premarket trading on Friday. Shares are on track to open in ...
With flu and COVID hospital admission rates now mirroring each other, Novavax, which lost out in the COVID vaccine race to Pfizer and Moderna, signed a licensing agreement with Sanofi to ...
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
Don’t call it a comeback: Novavax just (briefly) became a meme stock. The Maryland-based biotech joined the likes of Ango American, Vodafone and the notorious GameStop in a resurgence of the meme ...
Novavax (NASDAQ:NVAX) stock has more than doubled today and is up more than 120% at the time of this writing. This morning, the company announced a co-exclusive licensing agreement with Sanofi ...
Shares of Novavax jumped as much as 50% as Wall Street cheered a new multibillion-dollar deal with French drugmaker Sanofi that kicked off a dramatic turnaround for the struggling vaccine maker.
Sanofi will pay vaccine maker Novavax $500 million and take a small equity stake in the Maryland-based company as part of a broad COVID-19 shot alliance, the companies announced Friday. Through ...
This news sent a shockwave through the market, rewarding both long-term holders and savvy traders who capitalised on the short-term hype. But is this a sign of a long-term turnaround for Novavax ...
May 20 (Reuters) - Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's (NVAX.O) , opens new tab board, after the COVID-19 ...